Graft Polymer (uk) Share Discussion Threads

[smackeraim] 07/8/2024 23:27

"We've been working on programmes to try to see if we can improve acute, rapid-acting treatments with ketamine and with MDMA," explained Professor Nutt."There are two ways to do that. One is to develop new molecules, which is complex and expensive and needs a lot of investment. The other is to see if we can improve on the kinetics, and there are different ways of doing that. "You can get different routes – you can go through sublingually, you can go through buccally, you could go through the skin. But those different approaches need different formulations. Graph Polymer has a nanosphere formulation that they develop, which might begin to minimize some of the peripheral metabolism of both currently existing molecules, and you could potentially reformulate MDMA or ketamine. "If you develop new molecules, you want to optimize the kinetics, and that technology can be very helpful.""Optimising ketamine to make sure you get the optimal duration, speed of onset, speed of offset, and functional occupation of the brain, that's never been done before.""MDMA is less challenging because currently, the MDMA treatment takes all day."If you're giving someone MDMA therapy for PTSD, they come in at nine, they get the medicine at 10, and they don't leave till five or six. That's hugely tiring for the patient. It's stressful for the therapists, because you have got to have someone present all the time, and no one knows whether that's optimal."https://psychedelichealth.co.uk/2024/08/07/awakn-substance-use-mental-health-therapies-collaboration/

[smackeraim] 07/8/2024 13:29

Finally breaking low 0.2s

[smackeraim] 01/8/2024 07:39

yeah. its having a lot of churn in this low 20s area. I guess news will break it

[zen12] 01/8/2024 07:18

Not again...MMs dropped this now a million times to 21 from 24...enticing traders now!

[smackeraim] 31/7/2024 13:39

Nice swing blue on a lot of buying hmm

[smackeraim] 31/7/2024 09:59

yeah he's a good addition. we just await next news, they've so much IP there's going to be plenty

[purple11] 30/7/2024 11:02

heavyweight appointment Nutt on the advisory board.

[deltalo] 29/7/2024 13:23

Sorry wrong board, Should be on UGL.

[deltalo] 29/7/2024 13:21

It's going to fly and especially after the AGM when all is clear. Get in and enjoy the ride.

[purple11] 29/7/2024 09:05

im in

multibagger potential gl

[smackeraim] 29/7/2024 09:01

Blue, and looking lively

[ssrover] 28/7/2024 23:00

if you blocked me you blocked me.. no sense why as we’ve been on the same team at GST and now here .. GL

[ssrover] 28/7/2024 22:56

peter@shareresearcher

[smackeraim] 28/7/2024 22:48

you say I've blocked you on twitter. I've 298 blocked accounts. Tell me who you are

[ssrover] 28/7/2024 22:17

post from smacker.. i can’t open it as he’s blocked me but i’m sure it will be of interest as he’s usually on the ball

hxxps://x.com/smackeraim/status/1817666816870957351?s=46

[smackeraim] 26/7/2024 10:20

Could be a hell of a rise if news flow continues. They've got plenty to shout about

[ssrover] 26/7/2024 10:10

looking primed for a multibagger here

[stealive] 25/7/2024 14:37

Sellers out. Buy pressure should have an impact now.

[smackeraim] 25/7/2024 10:41

Buyers back. A day closer to more news.

[ssrover] 24/7/2024 08:09

certainly bud.. also you blocked me on twitter but we’ve never had cross words ?

[smackeraim] 24/7/2024 08:07

Hi ssrover feels like a big old re-rating is on the cards. hold for gold and all that

[ssrover] 23/7/2024 19:39

New management are sprinting out of the blocks on this one, what an impressive roster of newsflow. That's the proof for me that they've got something special up their sleeve.

The wonderfully tiny m/c is one of the delights here. And look how the share price has been moved around recently.

For me an easy hold: ignore the noise. Very juicy s/t targets over 1p. Let's see what they reveal. Atb

[ssrover] 23/7/2024 19:38

All of awakn lead compounds
Are novel and inventive.

They carried out the HtL

And the lead compounds are both novel and inventive and

Gpl are in for 40% of any revenues.


About Awakn’s Aminoindane NCEs

Aminoindanes are a class of molecules that offer an alternative source of medical empathogens to MDMA for use alongside psycho-social support in the treatment of trauma related mental health disorders.

Aminoindanes have similar pharmacological properties to MDMA, they promote serotonin dopamine and noradrenaline release and block their reuptake. This combination of effects is believed to underpin the empathogenic activity. They offer a novel patentable approach to the treatment of trauma-related disorders.

Awakn acquired six years of proprietary research data from Prof. David Nutt, this data described potentially fast acting aminoindane compounds

Awakn has completed a Hit to Lead (HtL) program with Evotec. In vitro and in vivo data shows efficacy for drug-like hits, defining chemical series for lead optimization. Awakn has filed patents for two promising chemical series identified for lead optimization

[ssrover] 23/7/2024 19:34

smackeraim.. heard your in this? Seems you me and Myles Mcknulty see big things here very soon..

Huge potential to multibag many times

[ssrover] 23/7/2024 14:48

Think about how much IP they own.. and patents pending

One of the last patents.. one of TONS they have.

The second provisional patent application, titled "Compositions and Methods for Treating Mental Health Disorders (MHDS) Using Depot Drug Delivery Systems (DDDS)", also focuses on the use of DDDS to reduce side effects and enhance effectiveness of therapeutics, in particular those used in treating mental health disorders such as Generalized Anxiety Disorder ("GAD"), Major Depressive Disorder ("MDD") and Post-Traumatic Stress Disorder ("PTSD").